EMA Authorised: Clopidogrel Krka (clopidogrel (as hydrochloride)) — Krka, d.d., Novo mesto

View source ↗

Summary

EMA authorised Clopidogrel Krka (clopidogrel hydrochloride) on 14 May 2025 for reducing cardiovascular events in patients with peripheral artery disease, stroke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Peripheral Artery Disease
• Stroke

Drugs mentioned

• Clopidogrel Krka (clopidogrel)

Snippet

Status: Authorised. Therapeutic area: Peripheral Vascular Diseases;Stroke;Myocardial Infarction. MAH: Krka, d.d., Novo mesto. Decision date: 14/05/2025